Company Products (9) Financing (2) Management (23)
 
ADETHERAPEUTICS INC.
BIOTECHGATE BY VENTURE VALUATION
Latest up-date: 08 Oct 2014
GENERAL INFORMATION
G
P
T
F
M
D
 
#19-410 Downey Rd.
Innovation Place Research Park
S7N4N1 Sakatoon
Canada, Saskatchewan
Contact person Mr. Sanj Singh, President & CEO
Company main phone +1 (306) 2615189
E-mail [available with subscription]
Website www.adetherapeutics.com
 
Founded (year) 2006
Source of foundation Independent foundation
   
Corporate description / mission
AdeTherapeutics is a privately-held clinical-stage drug development company. Its novel approach and drug platform currently focused on post operative fibrosis within women's health, gynecology, neurosurgery and orthopedics with the possibility of applications in other fibrotic diseases.
State of ownership Private / independent
Headquarters Yes
CATEGORIZATION
G
P
T
F
M
D
 
Main sector Biotechnology - Therapeutics and Diagnostics
Subsector(s)
  • Drug delivery
  • Peptides
Primary therapeutic area(s)
  • Skin and subcutaneous tissue
  • Musculoskeletal system and connective tissue
  • Genitourinary system
  • External causes of morbidity and mortality
 
Business model
  • In-licensing
  • Out-licensing
  • R&D
Customer segments
  • Large biotech & big pharma
  • Hospitals
SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES
G
P
T
F
M
D
 
No. of Biotech Products Pre-clinical Phase I Phase II Phase III On the market
  3 1 2 n/a n/a
No. of Medtech Products In development       On the market
  3       n/a
Description of products
Evitar is the lead product in a phase II (DBRCT) for prevention post operative fibrosis following abdominal surgeries. It corrects the imbalance in the system brought on by hypoxia due to surgical injury which triggers the cascading activation of many pro-inflammatory pathways (including TGF-Beta) that promote adhesion or fibrosis development. Restoring homeostasis within the first few critical hours after injury helps to inhibit the inflammatory pathways and promotes normal regeneration.
Special IP situation
Worldwide coverage in all major markets
FINANCING DETAILS
G
P
T
F
M
D
 
Money raised to date
(at least)
CAD 2.50M
Financing details
All privately financed.
COLLABORATIONS, CLIENTS & MARKETS
G
P
T
F
M
D
 
Partnering strategy / collaborations
Looking to exit after phase II trials...three additional products uses same technology platform and different formulations for separate indications
KEY
G
General profile
P
Products
T
Technologies
F
Financing rounds
M
Management
D
Deals
 
 
Click here to update this profile >>
© 2014 Venture Valuation  |  Impressum  |  Terms of Use & Privacy Policy  |  Print